bucindolol hydrochloride
AssetAlso called bucindolol, MJ-13105-1, GENCARO
Non-selective beta-adrenergic receptor antagonist with sympatholytic properties
- Stage
- Phase 2, no development reported
- Modality
- Small molecule
- Target
- ADRB2
- 1
- Indication
- 1
- Trial
- 1
- Developer
No development reported since December 2017. Last activity: Trial NCT01970501 completed. clinicaltrials.gov
Indications
1Current or recent history of atrial fibrillation
Phase 2, Completed, NCT01970501, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Target and mechanism5
- Owner and partners2
- Trials1
- Evidence for its targets5
- Competitors12
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.